Loading data for VRTX — first visit, this takes a few seconds.

Alerta

Vertex Pharmaceuticals (VRTX)

NasdaqGS: VRTX · Precio en tiempo real · USD

552.06

+23.87 (4.52%)

Al cierre: Aug 19, 2026, 8:00 PM

550.10

-0.36%

Fuera de horario: 7:59 PM

4.52% (1D)

No hay datos disponibles

Precio de compra	544.38
Capitalización de mercado	139.93B
Ingresos (TTM)	12.59B
Beneficio neto (TTM)	4.41B
Beta	0.30
EPS (TTM)	17.17
Ratio PER (TTM)	32.15
Adelante PE	25.31
P/B (TTM)	6.91
P/S (TTM)	11.11
Earnings Date	Nov 2, 2026

Precio de venta	545
Volumen	1,437,126
Volumen medio (20D)	1,567,301
Abierto	534.72
Anterior Cerrar	528.19
Rango del día	532.88 - 553.69
Rango de 52 semanas	374.17 - 553.69
analista	n/a
Precio objetivo	n/a
Dividendos	n/a
Fecha ex dividendo	n/a

Acerca de VRTX

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of...

[Leer más]

Industria Biotechnology

Sector Healthcare

IPO Fecha Jul 24, 1991

Empleados 6,400

Bolsa de Valores NasdaqGS

Símbolo bursátil VRTX

Sitio web https://www.vrtx.com

Perfil completo de la empresa

Desempeño financiero

En 2025, los ingresos de Vertex Pharmaceuticals fueron 12B, un aumento de 8.9% en comparación con 11.02B del año anterior. Las ganancias fueron 3.95B, una disminución de -838.09%.

Estados financieros

Sorpresa de resultados

Vertex Pharmaceuticals ha publicado sus resultados trimestrales en Aug 3, 2026:

Ingresos de $3.33B falla las estimaciones por $0, con 12.45% Crecimiento interanual.

EPS de 4.73 falla las estimaciones por -0.02, con 4.65% Crecimiento interanual.

Próxima publicación de resultados

Está previsto que Vertex Pharmaceuticals publique sus resultados el Nov 2, 2026, durante el horario de mercado.
Los analistas proyectan ingresos de ... Actualizar

Noticias

1 día hace · StockStory

3 Cash-Producing Stocks on Our Watchlist

Businesses with strong free cash flow tend to be more adaptable and resilient. Some of these companies shine bright by using their cash wisely to strengthen their market positions.

4 días hace · Insider Monkey

Can AbCellera Biologics (ABCL)’s Vertex Pharmaceuticals Incorporated (VRTX) Deal Turn its TCE Platform Into a Breakthrough?

On July 29, AbCellera Biologics Inc. (NASDAQ:ABCL) and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced a strategic collaboration to research, develop, and commercialize multispecific T-cel...

4 días hace · Simply Wall St.

Is Vertex Pharmaceuticals (VRTX) Fairly Valued As Pipeline Catalysts Near?

Vertex Pharmaceuticals stock has delivered a strong 5 year return, yet current checks suggest the market now prices it roughly in line with its fundamentals rather than as an obvious bargain. Recent n...

5 días hace · Motley Fool

Vertex Pharmaceuticals Just Hit an All-Time High. Here's Why the Biotech Stock Could Soar Even More

The drugmaker should significantly mitigate its most important risk as it develops new products.

5 días hace · Simply Wall St.

Vertex Pharmaceuticals (VRTX) Could Be 8% Undervalued Following Raised 2026 Guidance

Vertex Pharmaceuticals (VRTX) has drawn fresh attention after reporting second quarter 2026 results, raising full year revenue guidance to US$13.1b to US$13.2b, and completing a US$1.42b share repurch...

Página 1 de 2

Vertex Pharmaceuticals (VRTX)